Literature DB >> 18854315

Alternate mRNA splicing in multiple human tryptase genes is predicted to regulate tetramer formation.

Nicole E Jackson1, Hong-Wei Wang, Katherine J Bryant, H Patrick McNeil, Ahsan Husain, Ke Liu, Nicodemus Tedla, Paul S Thomas, Garry C King, Anusha Hettiaratchi, Jennifer Cairns, John E Hunt.   

Abstract

Tryptases are serine proteases that are thought to be uniquely and proteolytically active as tetramers. Crystallographic studies reveal that the active tetramer is a flat ring structure composed of four monomers, with their active sites arranged around a narrow central pore. This model explains why many of the preferred substrates of tryptase are short peptides; however, it does not explain how tryptase cleaves large protein substrates such as fibronectin, although a number of studies have reported in vitro mechanisms for generating active monomers that could digest larger substrates. Here we suggest that alternate mRNA splicing of human tryptase genes generates active tryptase monomers (or dimers). We have identified a conserved pattern of alternate splicing in four tryptase alleles (alphaII, betaI, betaIII, and deltaI), representing three distinct tryptase gene loci. When compared with their full-length counterparts, the splice variants use an alternate acceptor site within exon 4. This results in the deletion of 27 nucleotides within the central coding sequence and 9 amino acids from the translated protein product. Although modeling suggests that the deletion can be easily accommodated by the enzymes structurally, it is predicted to alter the specificity by enlarging the S1' or S2' binding pocket and results in the complete loss of the "47 loop," reported to be critical for the formation of tetramers. Although active monomers can be generated in vitro using a range of artificial conditions, we suggest that alternate splicing is the in vivo mechanism used to generate active tryptase that can cleave large protein substrates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18854315      PMCID: PMC2662235          DOI: 10.1074/jbc.M807553200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Identification and characterization of multiple forms of tryptase from human mast cells.

Authors:  R J Harvima; I T Harvima; D Dull; U K Dunder; L B Schwartz
Journal:  Arch Dermatol Res       Date:  1999 Feb-Mar       Impact factor: 3.017

2.  Diverse stability and catalytic properties of human tryptase alpha and beta isoforms are mediated by residue differences at the S1 pocket.

Authors:  Trevor Selwood; Zhi-Mei Wang; Darrell R McCaslin; Norman M Schechter
Journal:  Biochemistry       Date:  2002-03-12       Impact factor: 3.162

Review 3.  Alternative splicing and diversity of renal transporters.

Authors:  G Gamba
Journal:  Am J Physiol Renal Physiol       Date:  2001-11

4.  Human tryptases alpha and beta/II are functionally distinct due, in part, to a single amino acid difference in one of the surface loops that forms the substrate-binding cleft.

Authors:  C Huang; L Li; S A Krilis; K Chanasyk; Y Tang; Z Li; J E Hunt; R L Stevens
Journal:  J Biol Chem       Date:  1999-07-09       Impact factor: 5.157

5.  Elevated serum concentrations of beta-tryptase, but not alpha-tryptase, in Sudden Infant Death Syndrome (SIDS). An investigation of anaphylactic mechanisms.

Authors:  M G Buckley; S Variend; A F Walls
Journal:  Clin Exp Allergy       Date:  2001-11       Impact factor: 5.018

Review 6.  Inhibitors of tryptase for the treatment of mast cell-mediated diseases.

Authors:  K D Rice; R D Tanaka; B A Katz; R P Numerof; W R Moore
Journal:  Curr Pharm Des       Date:  1998-10       Impact factor: 3.116

7.  Structural requirements and mechanism for heparin-induced activation of a recombinant mouse mast cell tryptase, mouse mast cell protease-6: formation of active tryptase monomers in the presence of low molecular weight heparin.

Authors:  J Hallgren; D Spillmann; G Pejler
Journal:  J Biol Chem       Date:  2001-08-31       Impact factor: 5.157

8.  Potent selective nonpeptidic inhibitors of human lung tryptase.

Authors:  L E Burgess; B J Newhouse; P Ibrahim; J Rizzi; M A Kashem; A Hartman; B J Brandhuber; C D Wright; D S Thomson; G P Vigers; K Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

9.  Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study.

Authors:  W J Tremaine; A Brzezinski; J A Katz; D C Wolf; T J Fleming; J Mordenti; L C Strenkoski-Nix; M C Kurth
Journal:  Aliment Pharmacol Ther       Date:  2002-03       Impact factor: 8.171

10.  Human tryptase epsilon (PRSS22), a new member of the chromosome 16p13.3 family of human serine proteases expressed in airway epithelial cells.

Authors:  G W Wong; S Yasuda; M S Madhusudhan; L Li; Y Yang; S A Krilis; A Sali; R L Stevens
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

View more
  7 in total

Review 1.  Mast cell peptidases: chameleons of innate immunity and host defense.

Authors:  Neil N Trivedi; George H Caughey
Journal:  Am J Respir Cell Mol Biol       Date:  2009-11-20       Impact factor: 6.914

Review 2.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

Review 3.  Development of mast cells and importance of their tryptase and chymase serine proteases in inflammation and wound healing.

Authors:  Jeffrey Douaiher; Julien Succar; Luca Lancerotto; Michael F Gurish; Dennis P Orgill; Matthew J Hamilton; Steven A Krilis; Richard L Stevens
Journal:  Adv Immunol       Date:  2014       Impact factor: 3.543

Review 4.  The multifaceted mast cell in inflammatory bowel disease.

Authors:  Matthew J Hamilton; Sandra M Frei; Richard L Stevens
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

5.  Mast cell restricted mouse and human tryptase·heparin complexes hinder thrombin-induced coagulation of plasma and the generation of fibrin by proteolytically destroying fibrinogen.

Authors:  Alicia Prieto-García; Dominick Zheng; Roberto Adachi; Wei Xing; William S Lane; Kyungmee Chung; Paul Anderson; Philip M Hansbro; Mariana Castells; Richard L Stevens
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

6.  Alpha-tryptase gene variation is associated with levels of circulating IgE and lung function in asthma.

Authors:  A M Abdelmotelb; M J Rose-Zerilli; S J Barton; S T Holgate; A F Walls; J W Holloway
Journal:  Clin Exp Allergy       Date:  2014-06       Impact factor: 5.018

7.  Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance and Replication through Two Distinct Mechanisms.

Authors:  Sheng Ren; Jun Wang; Tie-Long Chen; Hao-Yu Li; Yu-Shun Wan; Nan-Fang Peng; Xi-En Gui; Ying Zhu
Journal:  PLoS One       Date:  2016-03-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.